Corcept Therapeutics Incorporated (CORT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Corcept Therapeutics Incorporated (CORT) has a cash flow conversion efficiency ratio of -0.026x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-16.77 Million) by net assets ($637.99 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Corcept Therapeutics Incorporated stock valuation for the company's overall valuation and market capitalisation.
Corcept Therapeutics Incorporated - Cash Flow Conversion Efficiency Trend (2003–2025)
This chart illustrates how Corcept Therapeutics Incorporated's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Corcept Therapeutics Incorporated Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Corcept Therapeutics Incorporated ranked by their cash flow conversion efficiency. Explore Corcept Therapeutics Incorporated (CORT) cash earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Strathcona Resources Ltd.
TO:SCR
|
0.044x |
|
Shenghe Resources Holding Co Ltd
SHG:600392
|
0.024x |
|
Youngor Group Co Ltd
SHG:600177
|
0.021x |
|
Linde India Limited
NSE:LINDEINDIA
|
0.093x |
|
BRF S.A
SA:BRFS3
|
0.142x |
|
PTC Therapeutics Inc
NASDAQ:PTCT
|
0.327x |
|
Taylor Morn Home
NYSE:TMHC
|
-0.002x |
|
West Fraser Timber Co Ltd
TO:WFG
|
-0.031x |
Annual Cash Flow Conversion Efficiency for Corcept Therapeutics Incorporated (2003–2025)
The table below shows the annual cash flow conversion efficiency of Corcept Therapeutics Incorporated from 2003 to 2025. View latest Corcept Therapeutics Incorporated stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $647.80 Million | $142.00 Million | 0.219x | -24.79% |
| 2024-12-31 | $679.59 Million | $198.07 Million | 0.291x | +16.25% |
| 2023-12-31 | $506.70 Million | $127.04 Million | 0.251x | +4.57% |
| 2022-12-31 | $501.84 Million | $120.32 Million | 0.240x | -46.33% |
| 2021-12-31 | $375.81 Million | $167.89 Million | 0.447x | +53.85% |
| 2020-12-31 | $523.34 Million | $151.97 Million | 0.290x | -20.81% |
| 2019-12-31 | $371.18 Million | $136.12 Million | 0.367x | -12.53% |
| 2018-12-31 | $275.88 Million | $115.67 Million | 0.419x | +31.39% |
| 2017-12-31 | $190.97 Million | $60.94 Million | 0.319x | -28.21% |
| 2016-12-31 | $41.38 Million | $18.39 Million | 0.444x | +162.67% |
| 2015-12-31 | $18.50 Million | $3.13 Million | 0.169x | -97.91% |
| 2014-12-31 | $-3.39 Million | $-27.38 Million | 8.080x | +558.26% |
| 2013-12-31 | $21.02 Million | $-37.06 Million | -1.763x | -202.41% |
| 2012-12-31 | $61.78 Million | $-36.02 Million | -0.583x | +25.93% |
| 2011-12-31 | $34.81 Million | $-27.40 Million | -0.787x | +24.96% |
| 2010-12-31 | $21.24 Million | $-22.29 Million | -1.049x | -28.98% |
| 2009-12-31 | $22.09 Million | $-17.97 Million | -0.813x | +25.11% |
| 2008-12-31 | $16.91 Million | $-18.36 Million | -1.086x | -45.95% |
| 2007-12-31 | $14.73 Million | $-10.96 Million | -0.744x | +79.63% |
| 2006-12-31 | $6.36 Million | $-23.24 Million | -3.654x | -463.80% |
| 2005-12-31 | $26.59 Million | $-17.23 Million | -0.648x | -117.07% |
| 2004-12-31 | $45.95 Million | $-13.72 Million | -0.299x | +69.43% |
| 2003-12-31 | $10.24 Million | $-10.00 Million | -0.977x | -- |
About Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type … Read more